ATE333881T1 - Verwendung von piperazin- phenothiazin- derivaten zur herstellung eines arzneimittels mit neuroprotektiven und/oder neurotropischen wirkungen auf das zns und/oder pns - Google Patents

Verwendung von piperazin- phenothiazin- derivaten zur herstellung eines arzneimittels mit neuroprotektiven und/oder neurotropischen wirkungen auf das zns und/oder pns

Info

Publication number
ATE333881T1
ATE333881T1 AT03291024T AT03291024T ATE333881T1 AT E333881 T1 ATE333881 T1 AT E333881T1 AT 03291024 T AT03291024 T AT 03291024T AT 03291024 T AT03291024 T AT 03291024T AT E333881 T1 ATE333881 T1 AT E333881T1
Authority
AT
Austria
Prior art keywords
hours
neuroprotective
pns
cns
piperazine
Prior art date
Application number
AT03291024T
Other languages
English (en)
Inventor
Aline Appert-Colin
Noelle Callizot
Original Assignee
Neuro3D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro3D filed Critical Neuro3D
Application granted granted Critical
Publication of ATE333881T1 publication Critical patent/ATE333881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT03291024T 2003-04-25 2003-04-25 Verwendung von piperazin- phenothiazin- derivaten zur herstellung eines arzneimittels mit neuroprotektiven und/oder neurotropischen wirkungen auf das zns und/oder pns ATE333881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291024A EP1470818B1 (de) 2003-04-25 2003-04-25 Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS

Publications (1)

Publication Number Publication Date
ATE333881T1 true ATE333881T1 (de) 2006-08-15

Family

ID=32946961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03291024T ATE333881T1 (de) 2003-04-25 2003-04-25 Verwendung von piperazin- phenothiazin- derivaten zur herstellung eines arzneimittels mit neuroprotektiven und/oder neurotropischen wirkungen auf das zns und/oder pns

Country Status (8)

Country Link
US (1) US20060276460A1 (de)
EP (1) EP1470818B1 (de)
AT (1) ATE333881T1 (de)
DE (1) DE60307049T2 (de)
DK (1) DK1470818T3 (de)
ES (1) ES2272911T3 (de)
PT (1) PT1470818E (de)
WO (1) WO2004096231A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2911143A1 (fr) * 2007-01-05 2008-07-11 Servier Lab Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
WO2013043744A2 (en) * 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US9814727B2 (en) 2014-03-10 2017-11-14 Universite D'aix-Marseille Piperazine phenothiazine derivatives for treating spasticity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3320245A (en) * 1964-08-21 1967-05-16 American Home Prod Derivatives of phenothiazine-10-glyoxylic acids and intermediates in the preparationthereof
US3320249A (en) * 1965-07-09 1967-05-16 Olin Mathieson Adamantyl derivatives of phenothiazines
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
AU708682B2 (en) * 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
US6514686B2 (en) * 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
WO1999007356A1 (en) * 1997-08-11 1999-02-18 University Of South Florida Research Foundation, Inc. Nicotine antagonists for neuropsychiatric disorders
FR2784678B1 (fr) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
US20030060487A1 (en) * 2000-04-12 2003-03-27 Bamdad R. Shoshana Treatment of neurodegenerative disease
CA2310205A1 (en) * 2000-05-29 2001-11-29 Dalhousie University Unknown
CA2418720A1 (en) * 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
AU2003222197A1 (en) * 2002-01-16 2003-09-02 The Regents Of The University Of California Inhibition of rna function
FR2835254B1 (fr) * 2002-01-25 2006-04-07 Sod Conseils Rech Applic Derives de thiazoles dans le traitement de maladies neurologiques

Also Published As

Publication number Publication date
PT1470818E (pt) 2006-11-30
DE60307049D1 (de) 2006-09-07
US20060276460A1 (en) 2006-12-07
EP1470818A1 (de) 2004-10-27
EP1470818B1 (de) 2006-07-26
DE60307049T2 (de) 2007-02-08
WO2004096231A2 (en) 2004-11-11
DK1470818T3 (da) 2006-11-20
HK1066741A1 (en) 2005-04-01
WO2004096231A3 (en) 2005-03-24
ES2272911T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
Vieira et al. Neural stem cell differentiation into mature neurons: mechanisms of regulation and biotechnological applications
Snow et al. Molecular and cellular characterization of the glial roof plate of the spinal cord and optic tectum: a possible role for a proteoglycan in the development of an axon barrier
DE3686927D1 (de) Neovaskularisierungsinhibitoren und deren herstellung.
EP1908842A3 (de) PEF-TU Expressionseinheiten
DE69602424D1 (de) Verwendung von carbazolverbindungen zur herstellung eines arzneimittels für die behandlung von kongestivem herzversagen
Walsh et al. Human central nervous system tissue culture: a historical review and examination of recent advances
ATE333881T1 (de) Verwendung von piperazin- phenothiazin- derivaten zur herstellung eines arzneimittels mit neuroprotektiven und/oder neurotropischen wirkungen auf das zns und/oder pns
WO2005046570A3 (en) Human stem cell materials and methods
CN108484795B (zh) 硫酸软骨素锂及其制备方法和应用
Fu et al. The potential roles of dental pulp stem cells in peripheral nerve regeneration
Swayne et al. Ion channels in postnatal neurogenesis: potential targets for brain repair
EP2357223A3 (de) Humane Stammzellen und Verfahren zur Verwendung
Zyuz’kov et al. The Role of cAMP-dependent intracellular signaling pathways in the regulation of the functions of neural stem cells and neuroglial cells in amyloid-β-induced neurodegeneration
Pranata et al. Brain-derived neurotrophic factor (BDNF) on cognitive function in the elderly: a literature review
CN107812171A (zh) 一种草本养护用治疗脱发的药物
NO996290L (no) 3-benzylpiperidiner
CN100344756C (zh) 一种体外诱导神经干细胞定向分化为胆碱能神经元的方法
Yoshida et al. Septal deafferentation enhances the neurotrophic effects of rat hippocampus on cultured neural cells from the central nervous system
DE602004011361D1 (de) Reversibel immortalizierte, olfaktorische nerven einschliessende glia zellen und deren verwendung zur förderung der nervenregenerierung
Muhlach et al. Target tissue control of nerve fiber growth rate and periodicity in vitro
Pierce et al. Developmental patterns of neurite outgrowth from chick embryo spinal cord and retinal neurons on laminin substrates
DE69008282T2 (de) Kaffeesäure-Derivate, deren Verwendung für medizinische Behandlungen und diese enthaltende pharmazeutische Zusammensetzungen.
Yang et al. Protein kinase C regulates neurite outgrowth in spinal cord neurons
CN110151997A (zh) 一种p53激活剂在制备治疗神经损伤药物中的应用
WO2021060652A1 (ko) 스타필로코커스 헤모리티쿠스 st-8 균주 및 그의 피부 상태 개선 용도

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties